GPP
TRML

Great Point Partners’s Tourmaline Bio TRML Stock Holding History

Great Point Partners’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-672,885
Closed -$17.6M – 43
2023
Q4 		$17.6M Buy
672,885
+572,885
+573% +$11.5M 3% 16
2023
Q3 		$2.81M Buy
100,000
+33,397
+50% +$978K 0.51% 39
2023
Q2 		$2.02M Buy
+66,603
New +$1.7M 0.4% 36

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Great Point Partners's TRML Position: Q1 2024 in Review

Great Point Partners sold out of Tourmaline Bio (TRML) in Q1 2024, closing a stake of 672,885 shares — an estimated $17.6M sold.

Great Point Partners first reported a position in TRML in Q2 2023 and held it in 3 quarters. The position peaked at $17.6M in Q4 2023. 96 funds tracked by Wall St. Rank hold TRML as of Q1 2024.

  • Great Point Partners reported no remaining Tourmaline Bio position as of Q1 2024 after selling out during the quarter.
  • Great Point Partners sold 672,885 Tourmaline Bio shares in Q1 2024, an estimated $17.6M.
  • Great Point Partners first reported a position in Tourmaline Bio in Q2 2023 and held it in 3 quarters.
  • Great Point Partners's Tourmaline Bio position peaked at $17.6M in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2024.

Based on Great Point Partners's 13F filing for Q1 2024, filed 15 May 2024.